NRX Pharmaceuticals (NRXP) Cash from Operations (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Cash from Operations of 4300000.0 for Q1 2026, down 23.56% year-over-year from 5625563.91 in Q1 2025, and down 16.18% quarter-over-quarter from 3701000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Cash from Operations (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Cash from Operations for 10 consecutive years, with 4300000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 23.56% year-over-year to 4300000.0; the TTM figure through Mar 2026 stood at 14920000.0 (down 42.83% YoY), while the FY2025 annual figure was 14100000.0, down 32.56% from the prior year.
- Cash from Operations fell to 4300000.0 in Q1 2026 per NRXP's latest filing, from 3701000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2098000.0 in Q4 2024 and bottomed at 14791000.0 in Q2 2022.
- Historically, Cash from Operations has averaged 5320529.41 across 5 years, with a median of 4028000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 244.28% — and 2024, when it surged 67.2%.
- NRX Pharmaceuticals' Cash from Operations stood at 8318000.0 in 2022, then surged by 61.63% to 3192000.0 in 2023, then surged by 34.27% to 2098000.0 in 2024, then sank by 76.41% to 3701000.0 in 2025, then declined by 16.18% to 4300000.0 in 2026.
- Business Quant data shows NRXP's Cash from Operations at 4300000.0 in Q1 2026, 3701000.0 in Q4 2025, and 2891000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -8.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.30 Mn |
| Mar 31, 2026 | -4.30 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -3.48 Mn |
| Mar 31, 2025 | -3.48 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Sep 30, 2024 | -2.31 Mn |
| Sep 30, 2024 | -2.31 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Dec 31, 2023 | -3.19 Mn |
| Dec 31, 2023 | -3.19 Mn |